Hengrui Pharma and GSK link across key therapeutic areas
The collaboration is poised to enhance Hengrui's globalisation strategy and provide GSK with significant growth opportunities beyond 2031.
GSK will pay an upfront fee of $500m, which includes licensing for the phosphodiesterase (PDE)3/4 programme.
The potential value of future success-based payments to Hengrui Pharma could be close to $12bn, assuming all programmes are optioned and milestones met. Hengrui Pharma is also set to receive tiered royalties on worldwide product net sales, with certain regional exclusions.
A highlight of the agreement is the worldwide licence for HRS-9821, a PDE3/4 inhibitor in clinical development for chronic obstructive pulmonary disease (COPD).
HRS-9821 aligns with GSK's goal to address a broad spectrum of COPD patients, including those with ongoing dyspnoea or those less likely to be prescribed inhaled corticosteroids or biologics.
In early trials, this inhibitor showed positive anti-inflammatory and bronchodilation effects. Its potential for a dry-powder inhaler formulation could integrate well with GSK's existing inhaled portfolio.
Hengrui Pharma executive vice-president and chief strategy officer Frank Jiang stated: 'GSK brings additional research and development expertise, a robust global clinical network and broad regulatory capabilities that will accelerate our PDE3/4 inhibitor as well as an array of other innovative therapy programmes to overseas markets, potentially delivering breakthrough treatments to patients globally."
Beyond HRS-9821, the collaboration includes up to 11 additional programmes.
Hengrui Pharma will spearhead the development up to Phase I trials, after which GSK may opt to develop further and commercialise the programmes globally, excluding mainland China, the Macau special administrative region (SAR), Hong Kong SAR and Taiwan.
This scaled collaboration is designed to expedite the development of innovative medicines, leveraging GSK's expertise and global reach alongside Hengrui Pharma's discovery and clinical evaluation capabilities.
The licensing of HRS-9821 is contingent upon customary regulatory clearances, including under the Hart-Scott-Rodino Act in the US.
In March 2025, MSD entered an exclusive licence agreement with Hengrui Pharma for the investigational oral small-molecule lipoprotein(a) [Lp(a)] inhibitor, HRS-5346.
"Hengrui Pharma and GSK link across key therapeutic areas" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
Chip design software provider Cadence raises annual sales forecast
(Reuters) -Cadence Design Systems raised its sales forecast for the year on Monday, after the U.S. lifted export curbs on chip design software to China earlier this month, allowing the company to resume sales to the key market. Shares of the San Jose, California-based company rose 7% in extended trading after rising about 10% this year. The company expects annual revenue between $5.21 billion and $5.27 billion, up from its earlier forecast of sales between $5.15 billion and $5.23 billion. "Cadence delivered excellent results for Q2, with broad-based strength across all businesses, more than offsetting the impact of the temporary restrictions on exports to China imposed on May 23rd," Chief Financial Officer John Wall said in a statement. Removal of the restrictions, which were announced late in May, allowed Cadence to again service the market that brings over 10% of revenue for the company, after an initial suspension of services to China had hurt sales and investor sentiment. The company reported revenue of $1.28 billion for the June quarter, beating analysts' average estimate of $1.25 billion, according to data compiled by LSEG.
Yahoo
6 minutes ago
- Yahoo
Is General Dynamics (GD) The Best Defense Stock to Buy in 2025?
General Dynamics Corp (NYSE:GD) is one of the . Citi's Jason Gursky named General Dynamics Corp (NYSE:GD) as one of the top stocks to benefit from the increasing defense spending in the US and Europe. The analyst believes the new contracts these companies are winning 'look more margin-accretive going forward.' Photo by Kevin Schmid on Unsplash Gursky mentioned specifically why he likes General Dynamics Corp (NYSE:GD): 'Shipbuilding is another area of focus. There's concern over the capacity gap between the U.S. and China, with China having far greater production capacity. That's why we're constructive on Huntington Ingalls and General Dynamics—they're positioned to benefit from investment in shipbuilding infrastructure.' While we acknowledge the potential of GD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
6 minutes ago
- Yahoo
Starbucks set to report 6th straight US sales decline as CEO Brian Niccol continues turnaround efforts
Starbucks (SBUX) is set to report results for its fiscal third quarter after the market close on Tuesday as CEO Brian Niccol continues turnaround efforts and the company is expected to extend its US sales slump while facing an uncertain consumer environment. Wall Street expects same-store sales to fall 1.5%, per Bloomberg data, which would mark the sixth consecutive quarter of declining sales and an acceleration from the previous quarter's 1% drop. US same-store sales are expected to fall 2.5% with a 4.5% decline in traffic. Analysts expect same-store sales in China will rise 2.1% in the quarter, marking the second straight quarter of positive growth for China as the company seeks out a partner in the region. Earlier this month, the company told Yahoo Finance it was "looking for a strategic partner with like-minded values ... and [wants] to retain a meaningful stake in the business." Adjusted earnings are expected to fall roughly 30% from a year ago to $0.65. Revenue is forecast to grow roughly 2% to $9.29 billion. Starbucks stock is up around 3% year to date, trailing behind the S&P 500's (^GSPC) 8.5% gain. Read more: Live coverage of corporate earnings Since joining the company last fall, Niccol has tried to change the fortunes of the coffee chain by cutting staff earlier this year and announcing plans this month to require more staff to be in the office four days per week. "While the magnitude of the savings offset remains in question, management was clear that the corporate cost structure of the business would continue to be closely examined to accommodate the necessary in-store and marketing investments that drive transaction growth," Stifel analyst Chris O'Cull wrote in a note to clients. CFO Cathy Smith told analysts on Starbucks' second quarter earnings call that she expected the company's third quarter sales to "follow normal seasonality" but did not provide a formal outlook. The company has also incentivized its management team to more aggressively turn around the business, offering executives performance-based stock grants focused on cutting costs. Wall Street will also be looking to hear more about Starbucks' new labor model in the US, innovations like its SummerBerry Refreshers and Iced Horchata Oatmilk Shaken Espresso, AI-powered assistants on in-store tablets, and the impact of price changes for drink modifications and app updates. Brooke DiPalma is a senior reporter for Yahoo Finance. Follow her on X at @BrookeDiPalma or email her at bdipalma@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
